You don't have to do it every day, right
The LEADER trial showed that liraglutide reduced the risk of major cardiovascular events in people with type 2 diabetes.[4] Soon after, SUSTAIN-6 demonstrated similar benefits with semaglutide.[5] Then came REWIND, which suggested that cardiovascular protection could extend even to patients without established cardiovascular disease.[6] The SELECT trial made headlines because it showed cardiovascular benefits in people with overweight or obesity who did not have diabetes, a finding that challenged long-held assumptions about who might benefit from these medicines.[7] Most recently, an international trial called SOUL, which tested an oral form of semaglutide, included 788 Indian patients across 32 centres
Structure of the human glucagon class B G-protein-coupled receptor
Embrace A medically supervised, affordable, results-driven weight loss program delivered 100% virtually
Discuss dose adjustment with your physician
Social media discussions often focus on dramatic outcomes, but medical evidence looks at a fuller picture: who may benefit, what side effects occur, how durable the results are, and whether the medicine is safe in the long term
